Curadim Pharma



Target: Curadim Pharma Co., Ltd.

Outline: R&D of pharmaceutical products

Investment: JPY 1 billion (maximum) / JPY 1.2 billion (maximum)
Announcement date of Investment: August 4, 2016 / June 4, 2018



SMBC Venture Capital Co., Ltd. Nippon Venture Capital Co., Ltd. Nissay Capital Co., Ltd. Mitsubishi UFJ Capital Co., Ltd. DBJ Capital Co., Ltd. Yamaguchi Capital Co., Ltd.

> 1st pipeline (CP1050) Multiple sclerosis treatment drug



Meiji Seika ファルマ


2nd pipeline (CP2090) Idiopathic pulmonary fibrosis treatment drug



Ube Industries, Ltd








Curadim Pharma


Curadim Pharma Co., Ltd.

The development of new drugs for intractable diseases such as multiple sclerosis. Curadim focuses on immunology in order to contribute to medical needs or unmet needs related to diseases for which a cure has not yet been found.



1st pipeline pharmaceutical company

Derived for each pipeline



2nd pipeline pharmaceutical company

- •Promote the creation of a new model case by providing support for spin-out ventures from the establishment stage in order to contribute to the development of early stage seeds from domestic pharmaceutical companies
- · Aim to promote open innovation by mobilizing resources and technological research in the pharmaceutical industry
- •Contribute towards solving societal issues by providing innovative pharmaceutical products for intractable diseases with high unmet medical needs